Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [4][6]. Core Views - The company is planning to acquire a controlling stake in Zhuhai Noah Changtian Storage Technology Co., Ltd., which will indirectly provide control over SkyHigh Memory Limited (SHM), a leading global 2D NAND enterprise. This acquisition is expected to enhance the company's storage product line and market reach [3]. - The actual controllers of the company are not participating in the pre-IPO share transfer, which involves approximately 5.58 million shares, accounting for 3.77% of the total share capital [2]. Financial Forecasts - The projected revenue for the company is expected to grow from 1,804 million yuan in 2024 to 3,124 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 26% [5][10]. - The net profit attributable to the parent company is forecasted to be 292 million yuan in 2024, dropping to 125 million yuan in 2025, and then recovering to 432 million yuan by 2027, indicating significant volatility in profitability [5][11]. - The earnings per share (EPS) is expected to fluctuate from 1.98 yuan in 2024 to 2.92 yuan in 2027, with a notable dip in 2025 [5][11]. Market and Product Strategy - The acquisition of SHM is anticipated to create synergies in product offerings, market expansion, and technological capabilities, thereby enhancing the company's competitive position in the global storage market [3]. - The company is optimistic about the recovery of the NOR Flash business and the increasing application of its products in AI edge computing, which supports the positive outlook for future growth [4].

Core Views - The A-share market experienced a collective decline on Friday, with the Shanghai Composite Index down 0.3%, the Shenzhen Component down 0.69%, and the ChiNext Index down 0.87. The total trading volume in the Shanghai and Shenzhen markets was 11,918.86 billion [2][7] - In terms of industry performance, beauty care, banking, and textile and apparel sectors led the gains, while electronics, computers, and defense industries faced declines. Concept sectors such as ST stocks, fentanyl, and sugar substitutes saw significant increases, while sectors like Sci-Tech innovation new stocks, storage chips, and DRG/DIP concepts faced declines [2][7] - The Hang Seng Index rose by 0.4%, while the Hang Seng Technology Index fell by 0.93%. In overseas markets, the Dow Jones fell by 0.29%, the S&P 500 decreased by 0.07%, and the Nasdaq remained unchanged [2][7] Important News - The high-level China-U.S. economic and trade talks held in Geneva from May 10 to 11 were described as candid, in-depth, and constructive, achieving important consensus and substantial progress. Both sides agreed to establish a consultation mechanism for economic and trade discussions [3][8] - The National Bureau of Statistics released April CPI and PPI data, indicating that the CPI rose by 0.1% month-on-month after a 0.4% decline in the previous month, while the year-on-year decline remained at 0.1%. The core CPI increased by 0.2% month-on-month and 0.5% year-on-year. The PPI fell by 0.4% month-on-month and 2.7% year-on-year, with the year-on-year decline widening by 0.2 percentage points compared to the previous month [3][8] Industry Analysis - The pharmaceutical sector has shown a divergence in performance since the beginning of the year, with the overall performance of various sub-sectors under pressure. Focus is on structural opportunities in the pharmaceutical sector, particularly in innovation, overseas expansion, and self-sufficiency [9] - The pharmaceutical index has outperformed the CSI 300 index by 3.76 percentage points, with the pharmaceutical sub-sectors showing varied performance. The chemical preparation sub-sector has increased by 8.90%, while medical services and pharmaceutical commerce have seen increases of 2.79% and 0.41%, respectively [10] - The overall revenue and net profit of the pharmaceutical sector are expected to decline in 2024 and Q1 2025, with several sub-sectors experiencing pressure on profit margins. However, the medical research outsourcing sector showed promising growth in Q1 2025 [11][12] Investment Recommendations - The pharmaceutical sector is expected to face overall revenue and net profit declines in 2024 and Q1 2025, with a focus on sub-sectors that show revenue growth, such as medical research outsourcing and hospitals. The chemical pharmaceutical sector has performed well in the secondary market, with attention on innovation-driven, domestic substitution, and policy immunity themes [13] - In the electronics sector, the SW electronics industry saw an increase in fund heavy positions in Q1 2025, with a focus on semiconductor self-sufficiency and AI computing applications. The top ten heavy stocks are primarily from the semiconductor and consumer electronics sectors, indicating institutional interest in self-sufficient semiconductor stocks [14][15] - Investment opportunities are highlighted in semiconductor self-sufficiency, AI computing, and AI edge applications, with a recommendation to focus on domestic semiconductor manufacturers and the growing demand for domestic computing capabilities [16]